Massachusetts Financial Services Co. MA Cuts Stock Holdings in Organon & Co. $OGN

Key Points

• Massachusetts Financial Services cut its stake in Organon by 27.6% in Q4, selling 2,619,936 shares and now holds 6,882,166 shares (about 2.65% of the company) valued at roughly $49.35 million.
• Organon missed Q4 estimates, reporting $0.63 EPS vs. $0.73 expected and $1.51B revenue vs. $1.52B (revenue down 5.3% YoY); analysts have an average rating of "Reduce" and an average price target of $8.50.
• The company pays a small quarterly dividend ($0.02; $0.08 annualized, ~0.9% yield) and trades with a market cap of about $2.26 billion, a P/E of 12.25, and a 12‑month range of $5.69–$13.24.

Massachusetts Financial Services Co. MA decreased its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 27.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,882,166 shares of the company's stock after selling 2,619,936 shares during the quarter. Massachusetts Financial Services Co. MA owned 2.65% of Organon & Co. worth $49,345,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in OGN. Foster Dykema Cabot & Partners LLC purchased a new stake in Organon & Co. in the third quarter worth approximately $29,000. Rothschild Investment LLC boosted its holdings in Organon & Co. by 73.1% in the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock worth $42,000 after purchasing an additional 1,646 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Organon & Co. by 70.2% in the third quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company's stock worth $53,000 after purchasing an additional 2,109 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Organon & Co. by 22.4% in the third quarter. GAMMA Investing LLC now owns 6,910 shares of the company's stock worth $74,000 after purchasing an additional 1,265 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in Organon & Co. by 188.0% in the third quarter. Hantz Financial Services Inc. now owns 7,702 shares of the company's stock worth $82,000 after purchasing an additional 5,028 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Trading Up 1.9%

Shares of OGN stock opened at $8.70 on Wednesday. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.24. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The firm's 50 day moving average is $6.95 and its 200 day moving average is $7.70. The stock has a market capitalization of $2.26 billion, a P/E ratio of 12.25, a P/E/G ratio of 0.79 and a beta of 0.67.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the previous year, the business posted $0.90 earnings per share. The firm's revenue was down 5.3% on a year-over-year basis. Research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were given a $0.02 dividend. The ex-dividend date was Monday, February 23rd. This represents a $0.08 annualized dividend and a yield of 0.9%. Organon & Co.'s dividend payout ratio (DPR) is presently 11.27%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on OGN shares. Zacks Research cut shares of Organon & Co. from a "hold" rating to a "strong sell" rating in a report on Thursday, January 29th. Barclays raised their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an "underweight" rating in a report on Tuesday, February 24th. Finally, Wall Street Zen cut shares of Organon & Co. from a "buy" rating to a "hold" rating in a report on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, Organon & Co. presently has an average rating of "Reduce" and an average price target of $8.50.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.